Giaconda Limited (GIA)

[Igor_Passau]

Giaconda Limited (Giaconda) is a research focused biotechnology company, engaged in research, development and commercialization of innovative therapeutics for gastrointestinal diseases and disorders. The company focuses broadly on research and development activities in the area of digestive diseases. The pipeline products of the company includes Myoconda, Hepaconda, Heliconda and Ibaconda, and one bowel evacuant Picoconda. Myoconda is a combination antibiotic therapy being developed in Phase III clinical trial for the treatment of crohn's disease. Hepaconda is a combination of bezafibrate and chenodeoxycholic acid. It is in Phase Phase II clinical study for the treatment of hepatitis c virus. Its Heliconda and Picoconda are undergoing Phase III Clinical Trials for the treatment of Resistant Helicobacter pylori infection and Bowel Preparation for

http://reports.pr-inside.com/giaconda-limited-gia-financial-and-r3189911.htm